Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, Yin M, Leppert D, Glanzman R, Tinbergen J, et al. Lancet. 2011 Nov 19; 378(9805):1779-87. Epub 2011 Oct 31. PMID: 22047971. Abstract CommentRecommendBookmarkWatch